Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

NCT00958906 | Withdrawn Phase 1

• 1 other identifier: GCO # 09-0611
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis.

Conditions

Uveitic Macular Edema; Intraocular Inflammation

Keywords

Infliximab; Uveitis; Macular Edema; Intraocular Inflammation

Outcome Measures

Primary Outcomes (1)

• Best-corrected visual acuity

  Three months

Secondary Outcomes (1)

• Macular thickness

  One, two, and three months

Study Arms (1)

Intravitreal infliximab

EXPERIMENTAL

Drug: Infliximab (intravitreal, 2.0mg/0.05ml)

Interventions

Infliximab (intravitreal, 2.0mg/0.05ml) DRUG

One injection of intravitreal infliximab (2.0mg/0.05ml).

Also known as: Remicade™

Intravitreal infliximab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be 18 years of age or older.
• Participant must understand and sign the protocol's informed consent document.
• Participants must have uveitic macular edema in one eye as defined by all of the following criteria:
• Presence of active intermediate uveitis or posterior uveitis.
• Macular edema defined as a central macular thickness of ≥ 250 μm on OCT.
• Uveitis must be noninfectious as determined by standard investigations used in the diagnostic investigation of uveitis.
• Participant must have visual acuity between 20/40 and hand motions in the study eye.
• Participant must have a steady fixation in the study eye and media clear enough for good quality imaging.
• Female participants of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must practice an adequate method of birth control. Males able to father a child must agree to practice birth control. Acceptable methods of birth control include hormonal contraception (birth control pills, injected hormones or vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom and spermicide) or surgical sterilization (hysterectomy, tubal ligation or vasectomy in a partner). If a participant is of childbearing potential, she must be willing to undergo monthly urine pregnancy tests. Both males and females must agree to use adequate birth control for three months after the intravitreal infliximab injection.

You may not qualify if:

• Participant is in another investigational study and actively receiving study therapy.
• Participant is unable to comply with study procedures or follow-up visits.
• Participant has uveitic macular edema (as defined above) in both eyes.
• Participant has multiple sclerosis or symptoms suggestive of multiple sclerosis.
• Participant has evidence of ocular disease other than uveitis in either eye that may confound the outcome of the study (e.g., diabetic retinopathy, age-related macular degeneration, vitreomacular traction, moderate/severe myopia, etc.).
• Participant is expected to need ocular surgery in the study eye during the course of the study.
• Participant has undergone ocular surgery or an intravitreal/periocular steroid injection in the study eye within the past 3 months.
• Participant has had a YAG laser capsulotomy or intravitreal anti-VEGF treatment in the study eye within the past 6 weeks.
• Participant has had a pars plana vitrectomy in the study eye.
• Participant is on ocular or systemic medications known to be toxic to the lens, retina, or optic nerve.
• Participant with a history of ocular herpes simplex virus infection in the study eye.
• A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).

Sponsors & Collaborators

• Icahn School of Medicine at Mount Sinai: lead

Study Sites (1)

Department of Ophthalmology, Mount Sinai School of Medicine

New York, New York, 10029, United States

Location

Related Publications (4)

• Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009 May;147(5):825-30, 830.e1. doi: 10.1016/j.ajo.2008.12.004. Epub 2009 Feb 10.

  PMID: 19211094 BACKGROUND

• Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):273-81. doi: 10.1007/s00417-008-0967-4. Epub 2008 Nov 4.

  PMID: 18982345 BACKGROUND

• Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl' Innocenti D, Moncini D, Menchini U. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1151-6. doi: 10.1167/iovs.07-0932.

  PMID: 18326743 BACKGROUND

• Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007 Sep;125(9):1221-4. doi: 10.1001/archopht.125.9.1221.

  PMID: 17846362 BACKGROUND

MeSH Terms

Conditions

Uveitis; Macular Edema

Interventions

Infliximab

Condition Hierarchy (Ancestors)

Uveal Diseases; Eye Diseases; Macular Degeneration; Retinal Degeneration; Retinal Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Farzin Forooghian, MD

  Icahn School of Medicine at Mount Sinai

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: August 11, 2009
• First Posted: August 13, 2009
• Study Start: August 1, 2009
• Study Completion: October 1, 2009
• Last Updated: June 23, 2011

Record last verified: 2011-06

Locations

US (1)